Connect your AI

Evolus EOLS Investing Cash Flow

Investing Cash Flow at other companies

AbbVieABBV

-$574M+21.9%

Other financials

Income statement

Revenue$73.1M+6.7%

Gross profit$48.9M+4.8%

Operating income-$6.8M+54.9%

Net income-$10.7M+43.5%

EPS (diluted)-$0.16+46.7%

Balance sheet

Cash & equivalents$49.8M-26.7%

Total debt$164.9M-4.1%

Total equity-$28.8M-336%

Total assets$220.6M+3.4%

Cash flow

Operating cash flow-$10.0M+36.3%

CapEx$415.0K+30.1%

Free cash flow-$10.4M+35.0%

Valuation

Market cap$470.86M-21.3%

Enterprise value$585.97M-16.6%

P/S1.6×-0.6×

Profitability

Gross margin66.1%-2.4pp

Operating margin-13.7%-1.9pp

Net margin-14.4%-3.3pp

FCF margin-9.6%-3.6pp

Returns & leverage

Return on equity-472.6%-1,534pp

Debt / equity22.2×—

Current ratio2×-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evolus's investing cash flow?: Evolus (EOLS) reported investing cash flow of -$1.69M in Q1 2026.
How has Evolus's investing cash flow changed year-over-year?: Evolus's investing cash flow increased by 9.1% year-over-year, from -$1.86M to -$1.69M.
What is the long-term trend for Evolus's investing cash flow?: Over 3 years (2022 to 2025), Evolus's investing cash flow has grown at a 42.2% compound annual growth rate (CAGR), from -$2.94M to -$8.45M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.